Literature DB >> 8871616

CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors.

B Agrawal1, M Reddish, B M Longenecker.   

Abstract

By direct or indirect immunofluorescence using FITC as a fluorochrome, 0 to 2% of the T cells isolated from peripheral blood of normal healthy individuals was found to be CD30+. Using indirect immunofluorescence and phycoerythrin-labeled Ab, higher percentages of CD30+ T cells (3-31%) were repeatedly found in the peripheral blood of normal healthy donors. The majority (85-90%) of CD30+ T cells obtained from PBLs of normal healthy donors were found in the CD8+ cell population. Following FACS sorting of the T cell populations into CD30+ and CD30- subpopulations, approximately 85 to 90% CD30+ T cells were CD8+, whereas the CD30- T cells were CD4+. Upon activation, the sorted CD30+ T cells produced both IFN-gamma and IL-4. In contrast to previous reports, these results demonstrate that CD30+CD8+ T cells are present in significant numbers in the PBLs of normal healthy individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871616

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Regulation of CD30 antigen expression and its potential significance for human disease.

Authors:  M E Kadin
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD).

Authors:  R Giacomelli; A Passacantando; I Parzanese; P Vernia; N Klidara; F Cucinelli; R Lattanzio; E Santori; P Cipriani; R Caprilli; G Tonietti
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

Review 3.  Deciphering CD30 ligand biology and its role in humoral immunity.

Authors:  Mary K Kennedy; Cynthia R Willis; Richard J Armitage
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

4.  Circulating CD30+CD4+ T Cells Increase Before Human Immunodeficiency Virus Rebound After Analytical Antiretroviral Treatment Interruption.

Authors:  Cecilia A Prator; Cassandra Thanh; Shreya Kumar; Tony Pan; Michael J Peluso; Ronald Bosch; Norman Jones; Jeffrey M Milush; Sonia Bakkour; Mars Stone; Michael P Busch; Steven G Deeks; Peter W Hunt; Timothy J Henrich
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

5.  Cowpox virus encodes a fifth member of the tumor necrosis factor receptor family: a soluble, secreted CD30 homologue.

Authors:  Joanne Fanelli Panus; Craig A Smith; Caroline A Ray; Terri Davis Smith; Dhavalkumar D Patel; David J Pickup
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

6.  Activated T cell subsets in human type 1 diabetes: evidence for expansion of the DR+ CD30+ subpopulation in new-onset disease.

Authors:  C Baker; L Chang; K A Elsegood; A J Bishop; D H Gannon; P Narendran; N J Leech; C M Dayan
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

7.  Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues.

Authors:  J Irsch; S Nitsch; M L Hansmann; K Rajewsky; H Tesch; V Diehl; A Jox; R Küppers; A Radbruch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

8.  Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies.

Authors:  Juan Pedro Kusanovic; Roberto Romero; Sonia S Hassan; Francesca Gotsch; Samuel Edwin; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Shali Mazaki-Tovi; Eleazar Soto; Nandor Gabor Than; Lara A Friel; Bo Hyun Yoon; Jimmy Espinoza
Journal:  J Matern Fetal Neonatal Med       Date:  2007-12

9.  Persistent HIV-1 replication does not explain low levels of T-cell interferon-gamma mRNA and elevated serum NO(2) (-)/NO(3) (-) in patients with stable CD4 T-cell responses to HAART.

Authors:  S Lee; C-A Almeida; M A H French; P Price
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

Review 10.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.